ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 195 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 1.55 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $221,000 | +10.0% | 4,260 | 0.0% | 0.02% | +11.1% |
Q2 2022 | $201,000 | -33.7% | 4,260 | 0.0% | 0.02% | -21.7% |
Q1 2022 | $303,000 | -5.0% | 4,260 | 0.0% | 0.02% | -4.2% |
Q4 2021 | $319,000 | +51.9% | 4,260 | -10.9% | 0.02% | +41.2% |
Q2 2021 | $210,000 | -11.0% | 4,780 | 0.0% | 0.02% | -19.0% |
Q1 2021 | $236,000 | +17.4% | 4,780 | 0.0% | 0.02% | +5.0% |
Q4 2020 | $201,000 | -8.2% | 4,780 | 0.0% | 0.02% | -16.7% |
Q3 2020 | $219,000 | -13.1% | 4,780 | +59.9% | 0.02% | -42.9% |
Q2 2019 | $252,000 | -11.9% | 2,990 | 0.0% | 0.04% | -16.0% |
Q1 2019 | $286,000 | – | 2,990 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |